Investigating auto-antibodies to predict Post Treatment Lyme Disease Syndrome
Auto-antibodies as predictive markers for Post treatment Lyme Disease Syndrome
This study is looking at how certain antibodies in the blood might help predict if someone will develop ongoing symptoms after being treated for Lyme disease, so we can find better ways to diagnose and help those who are affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10881966 on NIH RePORTER |
What this research studies
This research focuses on understanding how auto-antibodies, specifically those targeting host phospholipids, may serve as predictive markers for Post Treatment Lyme Disease Syndrome (PTLDS). The study will involve analyzing blood samples from patients who have been treated for Lyme disease to identify the presence and levels of these antibodies. By comparing patients who recover fully with those who develop PTLDS, researchers aim to uncover the role these antibodies play in the disease process. This could lead to better diagnostic tools and treatment strategies for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been diagnosed with Lyme disease and have completed antibiotic treatment but continue to experience symptoms.
Not a fit: Patients who have not been diagnosed with Lyme disease or those who have not undergone treatment are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and management of patients suffering from lingering symptoms after Lyme disease treatment.
How similar studies have performed: Previous research has indicated that auto-antibodies may play a role in other autoimmune conditions, suggesting potential for success in this novel approach to understanding PTLDS.
Where this research is happening
Boston, United States
- Tufts University Boston — Boston, United States (Active)
Researchers
- Principal investigator: Hu, Linden T — Tufts University Boston
- Study coordinator: Hu, Linden T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.